Back to results
US 2026/0297203 A1Published application
Treatment of thyroid eye disease with satralizumab
AssigneesChugai Seiyaku Kabushiki Kaisha, Genentech, Inc., Hoffmann-La Roche Inc.
InventorsTakatoshi Ozawa, Hiroaki Ida, Shunsuke Yoshida, Oluwatobi Idowu, Sian Lennon-Chrimes, Zdenka Haskova, Christopher Brittain
Life of this patent
Estimating the term…
Abstract
All currently available treatment options for thyroid eye disease (TED) carry substantial potential safety risks. The present disclosure provides a means for treating or preventing TED comprising an IL-6 inhibitor such as anti-IL-6 receptor antibody or antigen binding fragment thereof such as satralizumab.
Claims10
A method of treating or preventing thyroid eye disease (TED) in a subject, the method comprising administering to the subject an effective amount of satralizumab.
Dependencies are inferred from the claim text.